Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC

Video

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non-small cell lung cancer (NSCLC).

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, discusses the significance of the phase III FLAURA trial of first-line osimertinib (Tagrisso) in EGFR-mutant non—small cell lung cancer (NSCLC), during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.

The most important aspect of FLAURA is that a new-generation inhibitor can be superior to the standard first-generation standard of care in not just efficacy, but toxicity as well, Gandara explains.

Secondly, the data on patients with brain metastases highly favored osimertinib over the first-generation agents, he concludes.

<<< View more from the World Conference on Lung Cancer

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Adrianna Masters, MD, PhD,
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology